Tianjin Tianyao Pharmaceuticals Co., Ltd. Class A

Tianjin Tianyao Pharmaceuticals Co., Ltd. Class A

SSSE:600488
4.51
CNY
-0.10
(-2.17%)
0.07EPS
155.50P/E
7.30BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Tianjin Tianyao Pharmaceuticals Co., Ltd. Class A carries a market capitalization of 7.30B, placing it among publicly traded companies globally. Its enterprise value stands at 8.06B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap7.30B
Enterprise Value8.06B

Share Statistics

As of September 30, 2026, Tianjin Tianyao Pharmaceuticals Co., Ltd. Class A has 1.09B shares outstanding.

Shares Outstanding1.09B

Valuation Ratios

As of September 30, 2026, Tianjin Tianyao Pharmaceuticals Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 155.50. The price-to-sales ratio is 2.86, and the price-to-book ratio stands at 2.41.

PE Ratio155.50
PS Ratio2.86
PB Ratio2.41
P/TBV Ratio2.89

Enterprise Valuation

As of September 30, 2026, Tianjin Tianyao Pharmaceuticals Co., Ltd. Class A trades at an EV/EBITDA multiple of 104.74 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.17 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 104.74 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 8.06B versus a market cap of 7.30B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales3.17
EV / EBITDA104.74
EV / EBIT104.74

Financial Position

As of September 30, 2026, Tianjin Tianyao Pharmaceuticals Co., Ltd. Class A maintains a current ratio of 1.41, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 16.63, indicating elevated leverage, while an interest coverage ratio of 4.12 demonstrates adequate ability to service its debt obligations.

Current Ratio1.41
Quick Ratio0.51
Debt / Equity16.63
Debt / EBITDA8.34
Interest Coverage4.12

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 930,322.68 in revenue per employee across its workforce of 2,731.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee930,322.68
Employee Count2,731.00

Taxes

CNY

Over the twelve months ended September 30, 2026, Tianjin Tianyao Pharmaceuticals Co., Ltd. Class A recorded 3.95M in income tax expense. That works out to an effective tax rate of 5.14, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 76.96M, leaving 46.72M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax3.95M
Effective Tax Rate5.14

Stock Price Statistics

CNY

As of the close on November 17, 2026, Tianjin Tianyao Pharmaceuticals Co., Ltd. Class A's stock has gained approximately 0.67% over the past 52 weeks. The 50-day moving average sits at 5.48, while the 200-day moving average is 5.31.

52-Week Price Change0.67%
50-Day Moving Average5.48
200-Day Moving Average5.31

Income Statement

CNY

Over the twelve months ended September 30, 2026, Tianjin Tianyao Pharmaceuticals Co., Ltd. Class A generated 2.54B in revenue and converted that into 46.72M in net income, yielding earnings per share of 0.07. EBITDA reached 76.93M, while operating income came in at 201.65M.

Revenue2.54B
Gross Profit1.00B
Operating Income201.65M
Pretax Income76.96M
Net Income46.72M
EBITDA76.93M
EBIT76.93M
Earnings Per Share (EPS)0.07

Balance Sheet

CNY

As of September 30, 2026, Tianjin Tianyao Pharmaceuticals Co., Ltd. Class A holds 719.01M in cash and equivalents against 641.55M in total debt, resulting in a net debt position of -517.50M. Total book value stands at 3.03B, with working capital of 587.09M providing operational flexibility.

Cash & Cash Equivalents719.01M
Total Debt641.55M
Net Debt-517.50M
Equity (Book Value)3.03B
Book Value Per Share2.77
Working Capital587.09M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-41.67M

Margins

Over the twelve months ended September 30, 2026, Tianjin Tianyao Pharmaceuticals Co., Ltd. Class A posted a gross margin of 39.38, reflecting its pricing power and cost economics. The operating margin of 7.94 and net profit margin of 1.84 provide insight into operational efficiency.

Gross Margin39.38
Operating Margin7.94
Pretax Margin3.03
Profit Margin1.84
EBITDA Margin3.03

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Tianjin Tianyao Pharmaceuticals Co., Ltd. Class A paid dividends of 0.11 per share. The dividend payout ratio of 122.58 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 3.93, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Tianjin Tianyao Pharmaceuticals Co., Ltd. Class A shareholders.

Dividend Per Share0.11
Payout Ratio122.58
Shareholder Yield3.93

Stock Splits

Tianjin Tianyao Pharmaceuticals Co., Ltd. Class A's most recent stock split took place on March 13, 2013 with a 2:3 split ratio.

Last Split Date3/13/2013
Split Ratio2:3

Scores

As of September 30, 2026, Tianjin Tianyao Pharmaceuticals Co., Ltd. Class A has an Altman Z-Score of 3.68, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score3.68